Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need that is backed by University of Cambridge’s patient capital fund Cambridge Innovation Capital (CIC), has filed for an $86m initial public offering on the Nasdaq Global Market. Founded in 2009, Bicycle Therapeutics is developing treatments for conditions with a high unmet…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.